Risk of cancer in Turkish patients after treatment with TNF antagonists

Basit Öğe Kaydı
dc.contributor.authorPay, S.
dc.contributor.authorÖztürk, M. Akif
dc.contributor.authorCan, Gerçek
dc.contributor.authorCefle, Ayşe
dc.contributor.authorÇobankara, Veli
dc.contributor.authorErer, Burak
dc.contributor.authorYücel, Eftal
dc.date.accessioned2026-08-12T16:13:40Z
dc.date.issued2008
dc.departmentFırat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.doi10.1093/rheumatology/ken026
dc.identifier.endpage549
dc.identifier.issn1462-0324
dc.identifier.issue4
dc.identifier.pmid18296720
dc.identifier.scopus2-s2.0-43049166010
dc.identifier.scopusqualityQ1
dc.identifier.startpage548
dc.identifier.urihttps://doi.org/10.1093/rheumatology/ken026
dc.identifier.urihttps://hdl.handle.net/11508/43154
dc.identifier.volume47
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofRheumatology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260511
dc.subjectAdolescent; Adult; Antirheumatic Agents; Arthritis; Female; Humans; Male; Middle Aged; Neoplasms; Risk Assessment; Tumor Necrosis Factor-alpha; adalimumab; etanercept; infliximab; antirheumatic agent; tumor necrosis factor alpha; adult; ankylosing spondylitis; cancer risk; drug substitution; drug withdrawal; female; health survey; hematologic malignancy; human; juvenile rheumatoid arthritis; letter; major clinical study; male; priority journal; psoriatic arthritis; rheumatoid arthritis; risk assessment; risk factor; solid tumor; Turkey (republic); adolescent; arthritis; chemically induced disorder; clinical trial; drug antagonism; middle aged; multicenter study; neoplasm
dc.titleRisk of cancer in Turkish patients after treatment with TNF antagonists
dc.typeLetter

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu